ATIS-NVAF, NCT03062319: Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis |
|
|
| Terminated | 4 | 321 | Japan | Oral Anticoagulant, Antiplatelet Drug | National Hospital Organization Osaka National Hospital, Network for Clinical Stroke Trials, The BMS/Pfizer Japan Thrombosis Investigator Initiated Research Program | Ischemic Stroke, Atrial Fibrillation, Atherothrombosis | 07/23 | 07/23 | | |
| Recruiting | 3 | 860 | Europe, Canada, Japan, US | Recombinant Activated Factor VII (rFVIIa), NovoSeven, NiaStase, Placebo | Joseph Broderick, MD, Novo Nordisk A/S, National Institute of Neurological Disorders and Stroke (NINDS) | Intracerebral Hemorrhage | 01/28 | 01/28 | | |
